Viking Therapeutics Shares Plunge on Clinical Trial Setback

Viking Therapeutics shares are experiencing a severe sell-off, extending recent losses with a further 1.64% decline over the past trading session. The significant trading volume of 5.0 million shares indicates that investor sentiment remains decidedly negative, with no clear end to the downward pressure in sight.

The scale of the sell-off has been dramatic. On a monthly basis, the company’s equity has collapsed by 41.45%. When viewed over a longer horizon, the picture is even more bleak, with the stock posting a devastating annual loss of 64.07%. These figures cement Viking’s position as one of the biotechnology sector’s poorest performers this year.

Current trading sees the stock fluctuating between $22.96 and $24.14, a range that highlights both its extreme volatility and the... Read more...